Compare Amphastar Pharmaceuticals Inc (AMPH) vs Global E Online Ltd (GLBE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GLBE trades at $38.48, up 1.69% today, with a bullish technical signal from moving averages. The stock is supported by strong analyst consensus (14 buy ratings) and a recent $500 million share repurchase authorization. Revenue grew to $962.20 million in 2025, with net income of $68.27 million, and the company's acquisition of Passport aims to enhance logistics capabilities. The current price is near the consensus price target of $38.00.

The outlook remains positive driven by e-commerce growth and strategic acquisitions, though high valuation multiples (P/E of 57.43) pose a risk if growth slows. Key opportunities include expanding cross-border services, while risks involve execution of acquisitions and competitive pressures. Earnings have been mixed, with a recent miss in Q1 2026 against expectations.